Evaluate has integrated Brazilian regulatory and public sales data to provide our clients with insight into emerging markets and the pricing and volume dynamic behind Brazilian drug sales
Evaluateemploys rigorous methodologies to deliver strategic commercial analyses and strictly follows a standardized process to ensure high levels of data quality. These documents contain information around the sources used, coverage, and how data is processed (calculations, standardization, structures). Information around the methodologies used within the Evaluate Pharma & Biotech modules are listed below.
Evaluate created a Net Present Value tool to allow users to create, annotate and save multiple scenarios. The NPV module uses analyst consensus forecasts along with Evaluate’s algorithms for products across all major companies
Evaluate’s Epi Analyzer provides unique insights on the commercial value of an indication as well as patient populations, combining Evaluate’s expertise in consensus forecasts with a highly granular epidemiology database
The Adverse Events module monitors adverse events of post-marketed drugs and highlights potential changes to the FDA label. Changes to the label can impact prescribing patterns, patient compliance, marketing strategies and drug sales.
Evaluateprovides a Sales by Indication analysis on approximately 70% of the total Evaluate’s universe of products with sales to reveal the indication specific dynamic behind historic and forecast product sales
Evaluateprovides insight into the pricing and volume dynamic behind USA drug sales, integrating pricing and volume datasets and developing a proprietary methodology to reveal the volume and pricing measures on key drugs